思珀生物科技

Spot Biotechnology Ltd., founded in 2021, is an innovative biotechnology company focused on developing novel cellular product therapies. Leveraging foundational research from partners such as Ohio State University, Stanford University, MD Anderson Cancer Center, Memorial Sloan Kettering, Peking University, Anzhen Hospital, and Fuwai Hospital, the company has incubated and developed an innovative technology platform with its own intellectual property. Investors include IDG Capital, Shang Include Capital, LDVP, and Stanford University. The company's first GMP facility in Haining, Zhejiang province, spanning about 2,000 square meters, began operations in Q2 of 2022. CEO and Co-Founder, Andrew Lee, MD/PhD, earned his MD/PhD from Stanford University and has published more than 50 peer-reviewed journal papers on cell and gene therapy. He is also the founder of a medical innovation accelerator company with over 450 portfolio companies and more than $400 million in venture funds.